{{'Search' | translate}}
 

MOWIOL® 4-88 Reagent

Company: Merck
Catalog#: 475904
Bio-protocol()
Company-protocol()
Other protocol()

Murine Hair Follicle Derived Stem Cell Transplantation onto the Cornea Using a Fibrin Carrier
Author:
Date:
2018-05-20
[Abstract]  The goal of this protocol is to establish a procedure for cultivating stem cells on a fibrin carrier to allow for eventual transplantation to the eye. The ability to transfer stem cells to a patient is critical for treatment for a variety of disorders and wound repair. We took hair follicle stem cells from the vibrissae of transgenic mice expressing a dual reporter gene under the control of the Tet-on system and the keratin 12 promoter (Meyer-Blazejewska et al., 2011). A clonal growth assay was performed to enrich for stem cells. Once holoclones formed they were transferred onto a fibrin carrier and cultivated to obtain a confluent epithelial cell layer. Limbal stem cell deficient (LSCD) mice were used as the transplant recipient in order to test for successful grafting and ... [摘要]  该方案的目标是建立一种在纤维蛋白载体上培养干细胞以允许最终移植到眼睛的程序。 将干细胞转移给患者的能力对于治疗各种疾病和伤口修复至关重要。 我们在Tet-on系统和角蛋白12启动子(Meyer-Blazejewska等人,2011)的控制下从表达双报告基因的转基因小鼠的触须中取出毛囊干细胞。 进行克隆生长测定以富集干细胞。 一旦形成holoclones,将它们转移到纤维蛋白载体上并培养以获得融合上皮细胞层。 将角膜缘干细胞缺陷(LSCD)小鼠用作移植受体以测试移植成功和最终分化为角膜上皮表型。

【背景】干细胞被广泛用作治疗工具,因此递送手段是必不可少的。实际上,许多研究人员和公司正在寻找将细胞输送到人体内以优化细胞存活以及整合到宿主组织中的最佳方式。注射方法已广泛用于动物模型,但往往导致生存和整合差。目前正在使用利用生物材料和手术装置的技术。一种用于输送干细胞的技术是纤维蛋白载体。纤维蛋白凝胶是可降解的生物聚合物,其可粘附于允许细胞附着,迁移和增殖的天然组织(Ehrbar et al。,2005)。纤维蛋白凝胶具有许多优点,包括生物相容性,受控降解(Kjaergard等人,1994; Sidelmann等人,2000),均匀细胞分布和高细胞接种效率(Swartz ,2005)。已经将纤维蛋白凝胶用于治疗皮肤烧伤(Pellegrini等人,1999; ...

Primary Cultures from Human GH-secreting or Clinically Non-functioning Pituitary Adenomas
Author:
Date:
2018-04-05
[Abstract]  Pituitary adenomas are among the more frequent intracranial tumors usually treated with both surgical and pharmacological–based on somatostatin and dopamine agonists–approaches. Although mostly benign tumors, the occurrence of invasive behaviors is often detected resulting in poorer prognosis. The use of primary cultures from human pituitary adenomas represented a significant advancement in the knowledge of the mechanisms of their development and in the definition of the determinants of their pharmacological sensitivity. Moreover, recent studies identified also in pituitary adenomas putative tumor stem cells representing, according to the current hypothesis, the real cellular targets to eradicate most malignancies. In this protocol, we describe the procedure to establish primary cultures ... [摘要]  垂体腺瘤是更常见的颅内肿瘤之一,通常用基于生长抑素和多巴胺激动剂手术的手术和药物治疗。 虽然多为良性肿瘤,但侵入性行为的发生常常被检测到,导致预后较差。 来自人类垂体腺瘤的原代培养物的使用代表了对其发育机制的知识以及其药理敏感性决定因素的定义方面的显着进步。 此外,最近的研究也在垂体腺瘤中发现了假定的肿瘤干细胞,根据目前的假设,它代表了根除大多数恶性肿瘤的真实细胞靶标。 在这个协议中,我们描述了从人垂体腺瘤建立原代培养的程序,以及如何选择,体外扩增和表型鉴定推定的垂体腺瘤干细胞。

【背景】垂体腺瘤是最常见的颅内肿瘤之一(高达15%),横断面研究发现每100,000名居民中约有90例发病,其中绝大多数为30岁以上的成年人。大约10%的未经选择的垂体在尸检时进行了检查(即考虑到之前未诊断为垂体疾病的受试者的垂体)( ,Molitch,2017)。尽管通常为良性肿瘤,但垂体腺瘤的处理可因与激素分泌过多相关的临床综合征或发展以治疗抗性,高增殖率,快速复发和绒毛外侵袭为特征的侵袭行为而复杂化(Carreno等人,2017)。成年垂体干细胞的持续存在(Florio,2011)导致垂体腺瘤(以及可能的其他良性瘤形成)的发展可以源自具有干细胞特性(主要是自我更新和分化)的肿瘤细胞的亚群能力),正如已经建立的恶性固体和血液肿瘤一样。

最近的实验证据表明,癌症干细胞(CSC)范例也适用于人和小鼠垂体腺瘤(Donangelo等人,2014; ...

Comments